Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420139 | 1.00 | ABL1 (0.49) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL15766352 | 0.83 | ABL1 (0.53) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL10174510 | 0.81 | ABL1 (0.57) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL6420283 | 0.79 | ABL1 (0.49) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL6420281 | 0.79 | ABL1 (0.49) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL29752442 | 0.78 | ABL1 (0.54) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL942693 | 0.78 | ABL1 (0.54) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL8498644 | 0.78 | ABL1 (0.54) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL14466455 | 0.78 | ABL1 (0.50) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 | |
| SCHEMBL4278401 | 0.76 | ABL1 (0.51) | ABL1NR4A2HCRTR1HCRTR2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | ABL1 1133/4885NR4A2 268/4885HCRTR1 2788/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | ABL1 2293/4885NR4A2 159/4885HCRTR1 1683/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | ABL1 2432/4885NR4A2 158/4885HCRTR1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.